IDEXX Laboratories Beats Quarterly EPS and Revenue Estimates with 15% Pet Segment Growth
IDXX•IDEXX Laboratories delivered EPS of $3.47 and $1.14 billion in revenue, exceeding consensus estimates of $3.41 and $1.12 billion. Companion Animal Group sales grew 15% year-over-year and new IDEXX Cancer Dx™ platform momentum prompted a raised full-year 2026 outlook.
1. Quarterly Results
IDEXX Laboratories posted quarterly EPS of $3.47 versus the $3.41 consensus and revenue of $1.14 billion versus $1.12 billion expected, marking a 14% year-over-year revenue increase from $998.4 million.
2. Growth Drivers
Companion Animal Group sales rose 15% year-over-year, driven by strong adoption of software and imaging solutions alongside momentum from the new IDEXX Cancer Dx™ platform.
3. Outlook Revision
After four consecutive quarters of beats, the company raised its full-year 2026 revenue and EPS guidance, reflecting confidence in sustained demand across its diagnostics portfolio.
